Dogwood Therapeutics Inc (DWTX)

$5.26 +0.06 (1.15%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	12.06M
Revenue (ttm)	0.00
Net Income (ttm)	-12.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	19,800
Avg Vol	946,358
Day's Range	N/A - N/A
Shares Out	2.29M
Stochastic %K	13%
Beta	1.86
Analysts	Strong Sell
Price Target	$18.33

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 620 8655

Website: dwtx.com

Address:

44 Milton Avenue, Alpharetta, United States